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Introduction {#ehf212372-sec-0004}
============

Cachexia is an important co‐morbidity in cancer patients and an independent factor for impaired survival.[1](#ehf212372-bib-0001){ref-type="ref"} Cachexia is characterized by an involuntary weight loss due to the atrophy of skeletal muscle with or without loss of adipose tissue[2](#ehf212372-bib-0002){ref-type="ref"} affecting \~50--80% of patients with cancer and is the direct cause of 30% of cancer deaths.[3](#ehf212372-bib-0003){ref-type="ref"} Atrophy affects multiple organs including the heart. Although impaired cardiac function in cancer patients is usually attributed to cardiotoxicity of anti‐neoplastic therapies, the effects of cancer cachexia (CC) on cardiac atrophy and function have given rise to the hypothesis that CC itself results in cardiac atrophy and cardiac dysfunction, which lead to heart failure (HF), which is well supported by several pre‐clinical studies.[4](#ehf212372-bib-0004){ref-type="ref"}, [5](#ehf212372-bib-0005){ref-type="ref"}, [6](#ehf212372-bib-0006){ref-type="ref"}, [7](#ehf212372-bib-0007){ref-type="ref"}

Although several inflammatory, hormonal, and oxidative stress molecules have been suggested as markers of prognosis in cachexia,[8](#ehf212372-bib-0008){ref-type="ref"} there are no universally accepted specific biomarkers for this condition. This scenario becomes even more intriguing and complex considering that CC may lead to the development of HF, which appears as an additional contributing factor that exacerbates wasting in the cancer patients.[9](#ehf212372-bib-0009){ref-type="ref"}, [10](#ehf212372-bib-0010){ref-type="ref"} Although the field of HF biomarkers is rich and reflects different mechanisms of HF development and progression,[11](#ehf212372-bib-0011){ref-type="ref"} none of the available biomarkers are used to assess cardiac impairment in CC.[12](#ehf212372-bib-0012){ref-type="ref"}

Neutrophil gelatinase‐associated lipocalin (NGAL) is a 25 kDa secretory protein belonging to the lipocalins superfamily, which was initially identified as a component of neutrophil granules, associated with matrix metalloproteinase‐9[13](#ehf212372-bib-0013){ref-type="ref"} and later found to be expressed at low levels in several tissues.[14](#ehf212372-bib-0014){ref-type="ref"} Although the specific cellular role of NGAL is elusive, its expression is enhanced in tissues, plasma, and urine, in many pathological conditions, such as kidney failure and cancer.[15](#ehf212372-bib-0015){ref-type="ref"}, [16](#ehf212372-bib-0016){ref-type="ref"} NGAL expression has been documented to be highly up‐regulated at an early stage of kidney injury and rapidly detected in the circulation or in urine.[17](#ehf212372-bib-0017){ref-type="ref"} Thus, plasma and/or urinary NGAL levels might be diagnostic markers of early prediction of kidney injury.[18](#ehf212372-bib-0018){ref-type="ref"} Nevertheless, NGAL is not only specific for the kidney; in fact, it has been shown that urinary and blood NGAL levels might be up‐regulated by cardiac dysfunction, in patients with HF,[19](#ehf212372-bib-0019){ref-type="ref"}, [20](#ehf212372-bib-0020){ref-type="ref"} following acute myocardial infarction[21](#ehf212372-bib-0021){ref-type="ref"} and experimental HF.[22](#ehf212372-bib-0022){ref-type="ref"}

Recently, a clear link between NGAL and aldosterone has been reported, suggesting that NGAL is an aldosterone/mineralocorticoid receptor (MR)‐responsive gene. In fact, MR binds directly the promoter of NGAL, upon treatment with aldosterone, and controls its transcription, which is blocked by the MR antagonist spironolactone or by deletion of the hormone response element.[23](#ehf212372-bib-0023){ref-type="ref"} Moreover, acute or chronic administration of aldosterone induces cardiac NGAL expression and increased plasma NGAL *in vivo*.[23](#ehf212372-bib-0023){ref-type="ref"}, [24](#ehf212372-bib-0024){ref-type="ref"} High plasma level of aldosterone has also been reported in patients suffering from either non‐small cell lung or colorectal cancer, with or without cachexia or in experimental model of CC‐induced cardiomyopathy, resulting in cardiac remodelling due, at least in part, to increased aldosterone production.[6](#ehf212372-bib-0006){ref-type="ref"}

Although increased systemic and myocardial expression of NGAL has been reported in HF,[22](#ehf212372-bib-0022){ref-type="ref"} NGAL expression and its association with aldosterone levels have never been described in CC‐induced cardiomyopathy.

In the present study, we hypothesized that cancer cachectic rats would experience greater muscle and cardiac atrophy and greater cardiac dysfunction and be associated with higher cardiac NGAL expression than would sham‐treated and spironolactone‐treated rats. Moreover, we hypothesized a beneficial, dose‐dependent effect of spironolactone (5 vs. 50 mg/kg/day) on preservation of lean tissue and cardiac function in cancer cachectic rats.

Materials and methods {#ehf212372-sec-0005}
=====================

Animal model {#ehf212372-sec-0006}
------------

Juvenile male Wistar Han rats weighing 186.8 ± 1.1 g of 8 weeks of age were kept under standard laboratory conditions in a specific pathogen‐free animal facility and maintained at 22 ± 2°C with alternating 12 h light--dark cycle and free access to food and water. All the experimental procedures were performed in accordance with the European Commission guidelines for the animals used for scientific purposes.

Study design {#ehf212372-sec-0007}
------------

Rats were randomized into two groups and i.p. injected with either Yoshida 10^8^ AH‐130 hepatoma cells (*n* = 42) or saline (*n* = 9, sham). Tumour‐bearing rats were further divided and treated with placebo (*n* = 10) or with 5 (*n* = 16) or 50 mg/kg/day (*n* = 16) of the aldosterone antagonist spironolactone. Animals were orogastrically gavaged once daily over a period of maximum 16 days. Treatment with spironolactone or placebo started 1 day after tumour inoculation. Body weight and composition, as well as cardiac function, were assessed at baseline, before tumour inoculation. Cardiac function was re‐assessed on Day 11 after tumour inoculation. Body composition and body weight were recorded on Day 16 or the day of the euthanasia if the animals had to be sacrificed for ethical reasons. At the end of the study, the tumour was harvested from the peritoneum and its cell number evaluated using a Neubauer chamber. At the end of the study, plasma was collected, and organs were removed, weighed, and frozen in liquid nitrogen.

Body composition {#ehf212372-sec-0008}
----------------

Total body fat, lean mass, and body fluids were measured using the nuclear magnetic resonance spectroscopy device, EchoMRI‐700 (Echo Medical Systems, Houston, TX, USA), as described before.[4](#ehf212372-bib-0004){ref-type="ref"}

Echocardiography {#ehf212372-sec-0009}
----------------

Echocardiography was performed using the high‐resolution Vevo 770 system (VisualSonics Inc., Toronto, Canada), as described before.[4](#ehf212372-bib-0004){ref-type="ref"} Briefly, rats were anaesthetized with 1.5% isoflurane and laid in supine position on a heated surface to maintain body temperature and with all legs taped to electrocardiogram electrodes. Fur was removed from the chest using an electrical clipper and a chemical depilatory agent. Recordings were made in B‐mode and M‐mode to assess functional parameters, cardiac function, and dimensions.

Quantitative reverse transcription--PCR {#ehf212372-sec-0010}
---------------------------------------

Isolation of total RNA from heart was performed by TRIzol according to the manufacturer\'s protocol, and quantitative PCR analyses were performed as described.[25](#ehf212372-bib-0025){ref-type="ref"} Specific primers used for real‐time PCR were as follows: NGAL: 5′‐TCACCCTGTACGGAAGAACC‐3′ and 5′‐GGTGGGAACAGAGAAAACGA‐3′ (forward and reverse primers);β‐Actin: 5′‐TTCTACAATGAGCTGCGTGTG‐3′ and 5′‐CAGGTCCAGACGCAGGAT‐3′ (forward and reverse primers).

Protein extraction and sodium dodecyl sulfate polyacrylamide gel electrophoresis western blot {#ehf212372-sec-0011}
---------------------------------------------------------------------------------------------

Protein extraction and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS‐PAGE) western blot were performed as described before.[4](#ehf212372-bib-0004){ref-type="ref"} Approximately 50 mg of heart was homogenized in 500 μL ice‐cold lysis buffer \[20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM EGTA, 1% Triton X‐100, 2.5 mM Na~4~P~2~O~7~, 20 mM NaF, 1 mM dithiothreitol, 1 mM Na~3~VO~4~, 1 mM β‐glycerophosphate, and 10 μL/ml freshly added protease and phosphatase inhibitor cocktails\] and centrifuged at 18 400 rcf for 20 min at 4°C, and supernatant was collected. A total of 20 μL of the supernatant was used to determine the total protein concentration by Bradford assay (Quick Start Bradford 1× Dye reagent, Biorad \#500‐0205, Hercules, CA, USA) using bovine serum albumin (BSA) as a standard (Quick Start bovine serum albumin standard, Biorad \#500‐0206, Hercules, California, USA). Proteins were heat denatured for 5 min at 95°C in sample‐loading buffer (500 mM Tris/HCl pH 6.8, 30% glycerol, 10% SDS, 5% β‐mercaptoethanol, and 0.024% bromophenol blue), and 30 μg of protein lysate was resolved by SDS‐PAGE and transferred to nitrocellulose membranes (Amersham Protran 0.2 μm NC 10600001, Little Chalfont, UK). Membranes were blocked with Tris/HCl (pH 7.6) containing 0.1% Tween 20 and 5% BSA for 2 h and incubated overnight at 4°C with shaking with primary antibody against goat anti‐human/mouse/rat lipocalin‐2/NGAL (\#AF1757, R&D Systems, Minneapolis, MN, USA). Membranes were then washed in Tris‐buffered saline (pH 7.6) with 0.1% Tween 20 and incubated with horseradish peroxidase‐conjugated anti‐goat IgG secondary antibody (\#SC‐2020, Santa Cruz Biotechnology, Dallas, TX, USA) for 1 h at room temperature with shaking. Bound antibody was visualized using the chemiluminescent kit (ECL WB Detection, GE Healthcare RPN210601819, Little Chalfont, UK); immunoblot scanning and analyses were performed using an imaging system (UVITEC Imaging Systems, Cambridge, UK). Quantification of the bands was performed using the ImageJ software (NIH, Bethesda, MD, USA).

Measurement of plasma neutrophil gelatinase‐associated lipocalin and aldosterone levels {#ehf212372-sec-0012}
---------------------------------------------------------------------------------------

Plasma NGAL and aldosterone levels were determined by commercial enzyme‐linked immunosorbent assay kits (BioPorto Diagnostics, Gentofte, Denmark, for NGAL and Asbach Medical Products, Obrigheim, Germany, for aldosterone) according to manufacturers\' protocols.

Statistics {#ehf212372-sec-0013}
----------

Data were analysed with GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). Results are shown as mean ± SEM. Normality was tested using the D\'Agostino--Pearson test. Normally distributed data were analysed by one‐way ANOVA followed by Tukey\'s test, while data without normal distribution were analysed using Kruskal--Wallis ANOVA and subsequent Dunn\'s tests. Correlation analyses were assessed using Pearson\'s correlation coefficient. A *P*‐value of \<0.05 was considered significant.

Results {#ehf212372-sec-0014}
=======

Spironolactone reduces wasting in cancer cachexia {#ehf212372-sec-0015}
-------------------------------------------------

Baseline weight and lean and fat mass were similar in all the randomized groups before tumour inoculation (data not shown). As expected, tumour‐bearing rats lost a substantial amount of body weight, while sham animals gained weight. The weight loss was significantly attenuated by treatment with spironolactone in tumour‐bearing rats (*Figure* [*1*](#ehf212372-fig-0001){ref-type="fig"}). Both lean body mass and fat mass were protected from atrophy by spironolactone (*Figure* [*1*](#ehf212372-fig-0001){ref-type="fig"}). This protective effect was also seen on the level of individual muscles and tissues (*Table* [1](#ehf212372-tbl-0001){ref-type="table"}).

![(A--C) Effect of spironolactone treatment on body weight and body composition of the tumour‐bearing rats. The data are presented as mean ± SEM. \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. sham; ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001 vs. placebo. Sham *n* = 9, placebo *n* = 10, spironolactone spironolactone 5 mg/kg/day *n* = 16, spironolactone 50 mg/kg/day *n* = 16.](EHF2-6-89-g001){#ehf212372-fig-0001}

###### 

Tissue and muscle weight at the end of the study

                       Gastrocnemius (mg)                                                                                       Soleus (mg)                                                EDL (mg)                                                                                                Tibialis (mg)                                                                                           BAT (mg)                                                  WAT (mg)
  -------------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Sham                 1209 ± 40.1                                                                                              96.41 ± 3.2                                                104.5 ± 3.3                                                                                             441.11 ± 6                                                                                              271.1 ± 25.1                                              1170 ± 86.8
  Placebo              738.9 ± 27[\*\*\*](#ehf212372-note-0004){ref-type="fn"}                                                  69.18 ± 1.9[\*\*\*](#ehf212372-note-0004){ref-type="fn"}   63.8 ± 2.2[\*\*\*](#ehf212372-note-0004){ref-type="fn"}                                                 280.1 ± 10.2[\*\*\*](#ehf212372-note-0004){ref-type="fn"}                                               89.3 ± 6.6[\*\*\*](#ehf212372-note-0004){ref-type="fn"}   192.1 ± 35.4[\*\*\*](#ehf212372-note-0004){ref-type="fn"}
  5 mg/kg/day spiro    812.3 ± 50.5[\*\*\*](#ehf212372-note-0004){ref-type="fn"}                                                70.06 ± 3.1[\*\*\*](#ehf212372-note-0004){ref-type="fn"}   67.1.4 ± 1[\*\*\*](#ehf212372-note-0004){ref-type="fn"}                                                 294.9 ± 18[\*\*\*](#ehf212372-note-0004){ref-type="fn"}                                                 122.5 ± 17.3[\*\*](#ehf212372-note-0003){ref-type="fn"}   337.5 ± 110[\*\*\*](#ehf212372-note-0004){ref-type="fn"}
  50 mg/kg/day spiro   939.8 ± 8.1[\*\*\*](#ehf212372-note-0004){ref-type="fn"} ^,^ [\#](#ehf212372-note-0005){ref-type="fn"}   75.31 ± 3.1[\*\*\*](#ehf212372-note-0004){ref-type="fn"}   80.8 ± 5.4[\*\*\*](#ehf212372-note-0004){ref-type="fn"} ^,^ [\#](#ehf212372-note-0005){ref-type="fn"}   344.3 ± 19[\*\*\*](#ehf212372-note-0004){ref-type="fn"} ^,^ [\#](#ehf212372-note-0005){ref-type="fn"}   131.6 ± 16.8[\*](#ehf212372-note-0002){ref-type="fn"}     682.1 ± 93.3[\*\*\*](#ehf212372-note-0004){ref-type="fn"} ^,^ [\#](#ehf212372-note-0005){ref-type="fn"}

BAT, brown adipose tissue; EDL, extensor digitalis longus; WAT, white adipose tissue.

*P* \< 0.05.

*P* \< 0.01.

*P* \< 0.001 vs. sham.

*P* \< 0.05 vs. placebo.

Spironolactone prevents tumour‐induced cardiac dysfunction {#ehf212372-sec-0016}
----------------------------------------------------------

Baseline echocardiography was similar in all groups before tumour inoculation (*P* \> 0.1, data not shown). Tumour‐bearing animals displayed an overall deterioration of cardiac function: Cachectic animals, treated with placebo, compared with the control group, showed an impaired heart contractility reflected by fractional shortening (%) and ejection fraction (%), which were restored by 50 mg/kg/day of spironolactone (*Figure* [*2*](#ehf212372-fig-0002){ref-type="fig"} *A,B*). Also, the left ventricular stroke volume (LVSV), the LV end‐diastolic volume, and the cardiac output (CO) were significantly reduced in cachectic animals treated with placebo, compared with control rats, and significantly restored by spironolactone (*Figure* [*2*](#ehf212372-fig-0002){ref-type="fig"} *C--E*). Furthermore, spironolactone significantly protected the heart from the loss of LV diameter in diastole (*Figure* [*2*](#ehf212372-fig-0002){ref-type="fig"} *G*). Finally, the loss of LV mass, observed in tumour group treated with placebo, compared with sham rats, was abrogated by 50 mg/kg/day of spironolactone, whereas the 5 mg/kg/day dose was not effective (*Figure* [*2*](#ehf212372-fig-0002){ref-type="fig"} *H*).

![(A--H) Effect of spironolactone treatment in tumour rats on cardiac dimension and function. The data are presented as mean ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. sham; ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, vs. placebo; °*P* \< 0.05, °°*P* \< 0.01 vs. spiro 5. Sham *n* = 9, placebo *n* = 10, spironolactone 5 mg/kg/day *n* = 16, spironolactone 50 mg/kg/day *n* = 16. CO, cardiac output; LVEDD, left ventricular end‐diastolic diameter; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction ; LVESD, left ventricular end‐systolic diameter; LVFS, left ventricular fractional shortening; LVSV, left ventricular stroke volume.](EHF2-6-89-g002){#ehf212372-fig-0002}

Plasma levels of aldosterone and neutrophil gelatinase‐associated lipocalin {#ehf212372-sec-0017}
---------------------------------------------------------------------------

Plasma aldosterone was up‐regulated from 337 ± 7 pg/mL in sham animals to 591 ± 31 pg/mL in the placebo group (*P* \< 0.001 vs. sham; *Figure* [*3*](#ehf212372-fig-0003){ref-type="fig"}). Treatment with 50 or 5 mg/kg/day of spironolactone reduced aldosterone plasma level to 396 ± 22 and 391 ± 25 pg/mL, respectively (*P* \< 0.01 vs. placebo; *Figure* [*3*](#ehf212372-fig-0003){ref-type="fig"}).

![Aldosterone plasma levels were elevated in rats with cancer cachexia and reduced by spironolactone. *White bars*, sham; *black bars*, placebo; *grid lines bars*, spironolactone 5 mg/kg/day; *grey bars*, spironolactone 50 mg/kg/day. The data are presented as mean ± SEM. \*\*\**P* \< 0.001, ^\#\#^ *P* \< 0.01 vs. placebo. Sham *n* = 9, placebo *n* = 10, spironolactone 5 mg/kg/day *n* = 16, spironolactone 50 mg/kg/day *n* = 16.](EHF2-6-89-g003){#ehf212372-fig-0003}

NGAL mRNA expression and protein levels were up‐regulated in the hearts of cachectic animals, treated with placebo, compared with sham rats (*P* \< 0.05 vs. sham for mRNA, *Figure* [*4*](#ehf212372-fig-0004){ref-type="fig"} *A*, and *P* \< 0.01 vs. sham for protein level, *Figure* [*5*](#ehf212372-fig-0005){ref-type="fig"}). Treatment of the tumour‐bearing rats with 50 mg/kg/day of spironolactone reduced significantly cardiac NGAL mRNA expression (*P* \< 0.05 vs. placebo; *Figure* [*4*](#ehf212372-fig-0004){ref-type="fig"} *A*) and NGAL protein levels (*P* \< 0.001 vs. placebo *Figure* [*5*](#ehf212372-fig-0005){ref-type="fig"}), while 5 mg/kg/day of spironolactone had no effect on cardiac NGAL expression (*Figures* [*4*](#ehf212372-fig-0004){ref-type="fig"} *A* and [*5*](#ehf212372-fig-0005){ref-type="fig"}). Plasma levels of NGAL were increased in tumour‐bearing rats (1.462 ± 0.3603 μg/mL; *Figure* [*4*](#ehf212372-fig-0004){ref-type="fig"} *B*) compared with controls (0.0936 ± 0.006 μg/mL, *P* \< 0.001; *Figure* [*4*](#ehf212372-fig-0004){ref-type="fig"} *B*). Spironolactone, 50 mg/kg/day, reduced NGAL levels to 0.5296 ± 0.07 μg/mL (*P* \< 0.05 vs. placebo; *Figure* [*4*](#ehf212372-fig-0004){ref-type="fig"} *B*), whereas 5 mg/kg/day had no effect (*Figure* [*4*](#ehf212372-fig-0004){ref-type="fig"} *B*).

![Neutrophil gelatinase‐associated lipocalin (NGAL) mRNA expression in the (A) heart and (B) plasma levels in cachectic rats. *White bars*, sham; *black bars*, placebo; *grid lines bars*, spironolactone 5 mg/kg/day; *grey bars*, spironolactone 50 mg/kg/day. The data are presented as mean ± SEM. \*\*\**P* \< 0.001, \**P* \< 0.05 vs. sham; ^\#^ *P* \< 0.05 vs. placebo; °*P* \< 0.05 vs. 5 mg/kg/day. Sham *n* = 9, placebo *n* = 10, spironolactone 5 mg/kg/day *n* = 16, spironolactone 50 mg/kg/day *n* = 16.](EHF2-6-89-g004){#ehf212372-fig-0004}

![Neutrophil gelatinase‐associated lipocalin (NGAL) protein expression in the heart. *White bars*, sham; *black bars*, placebo; *grid lines bars*, spironolactone 5 mg/kg/day; *grey bars*, spironolactone 50 mg/kg/day. The data are presented as mean ± SEM. \*\**P* \< 0.01, vs. sham; ^\#\#\#^ *P* \< 0.05 vs. placebo; °*P* \< 0.05 vs. 5 mg/kg/day. Sham *n* = 9, placebo *n* = 10, spironolactone 5 mg/kg/day *n* = 16, spironolactone 50 mg/kg/day *n* = 16.](EHF2-6-89-g005){#ehf212372-fig-0005}

Increased plasma aldosterone in placebo group correlated positively to plasma NGAL (*r* = 0.693, *P* \< 0.05; *Figure* [*6*](#ehf212372-fig-0006){ref-type="fig"} *A*) and increased cardiac NGAL mRNA expression (*r* = 0.866, *P* \< 0.01; *Figure* [*6*](#ehf212372-fig-0006){ref-type="fig"} *B*) and cardiac protein levels (*r* = 0.838, *P* \< 0.01; *Figure* [*6*](#ehf212372-fig-0006){ref-type="fig"} *C*).

![Relationship between plasma aldosterone and plasma NGAL (A), NGAL cardiac mRNA expression (B), and NGAL cardiac protein levels (C) by Pearson‐related analysis. Lines are generated by regression analyses (GraphPad Prism); *r*  =  Pearson correlation coefficient. NGAL, neutrophil gelatinase‐associated lipocalin.](EHF2-6-89-g006){#ehf212372-fig-0006}

Discussion {#ehf212372-sec-0018}
==========

Here, we have demonstrated that (i) the Yoshida hepatoma model of CC caused wasting and weight loss as well as increased aldosterone levels in plasma and cardiac tissue. (ii) This metabolic alteration was associated with a cardiac dysfunction (reduced ventricular ejection fraction, LVSV, CO), suggesting a close relationship between cardiac and skeletal muscle atrophy and cardiac function.[26](#ehf212372-bib-0026){ref-type="ref"} (iii) CC caused an increase in aldosterone that was accompanied by an increase in levels of cardiac and plasma NGAL. (iv) Administration of spironolactone reduced wasting and weight loss and prevented further cardiac dysfunction with a decrease in heart and plasma levels of aldosterone and NGAL.

Physiologically, NGAL is involved in the synthesis of prostaglandins, modulation of immune response, and regulation of cell growth and metabolism; on the other hand, its overexpression represents a consequence of malignancies, such as hepatocellular carcinomas,[25](#ehf212372-bib-0025){ref-type="ref"} and its increased levels in plasma and urine are characteristic in patients suffering from HF. Accordingly, it has been demonstrated that NGAL may be up‐regulated in 'stressed' cardiomyocytes in response to pro‐inflammatory cytokines and free radical overproduction.[27](#ehf212372-bib-0027){ref-type="ref"}

Several clinical studies showed that patients with cardiovascular diseases present increased plasma aldosterone levels and that, blocking its receptor, their mortality was reduced.[28](#ehf212372-bib-0028){ref-type="ref"} Supporting this theory, aldosterone plasma levels are up‐regulated in patients suffering from cancer, with or without cachexia.[6](#ehf212372-bib-0006){ref-type="ref"} Further evidence shows that excessive MR activation is a hallmark of a number of cardiovascular diseases that may benefit from treatments with MR antagonists.[29](#ehf212372-bib-0029){ref-type="ref"} We have demonstrated that CC‐dependent cardiac dysfunction was accompanied by an increase in heart and plasma aldosterone levels, which was reverted by spironolactone treatment. Interestingly, blockade of the MR was also able to reduce NGAL. These results suggested that the enhanced levels of both molecules, in either tissue or circulating form, may be involved in the onset and the progression of cardiomyopathy. Our hypothesis is supported and strengthened by recent studies providing evidence that NGAL represents a mineralocorticoid‐target gene in the cardiovascular system. Indeed, an excess of mineralocorticoids caused NGAL overexpression in the heart, aorta, and plasma through the binding of activated MR to the NGAL promoter.[23](#ehf212372-bib-0023){ref-type="ref"}

Although spironolactone was able to inhibit aldosterone levels dose dependently, we observed that it did not affect NGAL expression in the same manner, suggesting that the protective down‐regulation of NGAL against cardiac dysfunction, at higher doses of spironolactone, could be exerted through an additional protective mechanism, independent of aldosterone. Accordingly, recent evidence highlights a direct role for spironolactone in preventing the development of inflammatory cardiovascular disease, differently by MR, which involves the inhibition of inflammation. Several factors might contribute to determine NGAL expression levels, either in physiological situations or in pathology. It has been shown that nuclear factor (NF)‐κB can directly enhance NGAL expression[30](#ehf212372-bib-0030){ref-type="ref"}, [31](#ehf212372-bib-0031){ref-type="ref"} and that the direct suppression of NF‐κB, by high dose of spironolactone, independent of the MR, might justify the protective down‐regulation of NGAL against cardiac dysfunction. It has been shown that MR binding is not involved in spironolactone‐induced suppression of NF‐κB activity[29](#ehf212372-bib-0029){ref-type="ref"} and that this effect could be mediated by the degradation of the ATP‐dependent DNA helicase XPB, able to suppress both NF‐κB and AP‐1 signalling.[32](#ehf212372-bib-0032){ref-type="ref"} Thus, data from humans,[33](#ehf212372-bib-0033){ref-type="ref"} animal models,[34](#ehf212372-bib-0034){ref-type="ref"} and *in vitro* studies[35](#ehf212372-bib-0035){ref-type="ref"} show a clear role of aldosterone‐induced oxidative stress[28](#ehf212372-bib-0028){ref-type="ref"} that, together with the overexpression of NGAL, might explain the cardiac damage induced by the enhanced aldosterone levels caused by hepatocellular carcinoma.[36](#ehf212372-bib-0036){ref-type="ref"}, [37](#ehf212372-bib-0037){ref-type="ref"} Moreover, it has been hypothesized that NGAL overexpression is associated with advanced cardiac dysfunction and might affect Nrf2 regulation, causing the failure to maintain the redox homeostasis by antioxidant enzymes. In turn, the persistently oxidative stress results in cardiac remodelling and finally HF.[38](#ehf212372-bib-0038){ref-type="ref"} Recent evidence revealed a direct correlation between NGAL levels and cardiac tissue damage, suggesting that NGAL levels can reflect several cardiovascular diseases including hypertensive cardiac hypertrophy,[39](#ehf212372-bib-0039){ref-type="ref"} coronary artery disease,[40](#ehf212372-bib-0040){ref-type="ref"} and acute HF.[41](#ehf212372-bib-0041){ref-type="ref"} Human studies revealed a central role for NGAL in the onset and development of cardiac hypertrophy and HF, which was independent of renal function.[39](#ehf212372-bib-0039){ref-type="ref"} CC, induced by the Yoshida hepatoma, drives to a 'non‐canonical' form of cardiomyopathy, where cardiac wasting is the hallmark.[6](#ehf212372-bib-0006){ref-type="ref"} Thus, here, we present an animal model of cancer cachectic cardiomyopathy without LV hypertrophy and dilatation, with elevated NGAL levels, that may be connected to cardiac damage and dysfunction.

Although plasma NGAL has achieved a clinical significance only as a biomarker of cardiovascular disease in patients with chronic kidney disease,[40](#ehf212372-bib-0040){ref-type="ref"} latter discoveries, together with our study, suggest that NGAL may be considered as a potential biomarker able to detect the development of heart dysfunction and HF.

Symptoms of CC are shortness of breath, fatigue, and impaired exercise capacity, representing typical signs of HF.[6](#ehf212372-bib-0006){ref-type="ref"} Growing evidence shows that aldosterone and MR contribute to the endocrine basis of HF, regulating the expression of several genes implicated in pathologic cardiac remodelling, which can be inhibited by pharmacologic blockers of translation and transcription and/or by MR antagonist drugs,[42](#ehf212372-bib-0042){ref-type="ref"} although the beneficial properties of high doses of spironolactone on skeletal muscle mass depend on its ability to inhibit aldosterone effects. In fact, evidence exists that in patients suffering from congestive HF, the treatment with angiotensin‐converting enzyme inhibitors and AT‐1 receptor antagonists induces an amelioration in exercise capacity mediated by a change in myosin heavy chain (MHC) composition. In particular, slow MHC1 increased as compared with fast oxidative MHC2a and fast glycolytic MHC2b isoforms, and this enhancement correlated with the net peak V(O~2~) gain.[43](#ehf212372-bib-0043){ref-type="ref"}

Thus, our results suggest that, although under CC atrophy seems to affect predominantly glycolytic fibres,[44](#ehf212372-bib-0044){ref-type="ref"}, [45](#ehf212372-bib-0045){ref-type="ref"} the favourable shift in contractile proteins towards fatigue‐resistant oxidative fibres, occurring in the skeletal muscle after spironolactone administration, might imply an improved exercise capacity, thus ameliorating the quality of life of cancer patients with HF.

Conclusions {#ehf212372-sec-0019}
===========

In summary, we demonstrate that CC‐induced increases in aldosterone levels may contribute to enhanced expression of plasma and cardiac expression of NGAL, which are also associated with worse cardiac function. Therefore, spironolactone treatment may greatly attenuate cardiac dysfunction and lean mass atrophy associated with CC.
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